vornorexant

Vornorexant (TS-142, ORN-0829) is a novel dual orexin receptor antagonist (DORA) developed by Taisho Pharmaceutical for the treatment of insomnia and sleep apnea. It acts as an antagonist at both orexin OX1 and OX2 receptors with high potency (IC50 values of 1.05 nM for OX1 and 1.27 nM for OX2). The drug is designed to be rapidly absorbed with a short plasma half-life (approximately 1.3–3.3 hours), aiming to reduce next-day residual effects such as somnolence. Vornorexant is administered orally and has shown significant efficacy in improving sleep onset latency and wake after sleep onset in clinical trials[1][2][4][5].

Other names

vornorexantORN-0829ORN0829ORN 0829TS 142TS142TS-142